Lyell Immunopharma, Inc. Increase (Decrease) in Deferred Revenue
Lyell Immunopharma, Inc. (LYEL) reported Increase (Decrease) in Deferred Revenue of -$7.70 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2021-11-12
- Lyell Immunopharma, Inc. increase (decrease) in deferred revenue for the quarter ending 2021-09-30 was -$2.64M.
- Lyell Immunopharma, Inc. increase (decrease) in deferred revenue for the quarter ending 2020-09-30 was -$1.07M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month |
|---|---|---|---|
| 2021-09-30 | -$2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$7.70M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$5.06M 10-Q · filed 2021-08-12 | ||
| 2020-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$5.44M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$4.37M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |